top of page
  • Active, not recruiting

NCT04184050: Phase 1/2: Dose Esc. & Dose Exp. of safety, Tolerability & PK of HPN217 in RRMM

Updated: Feb 10

  • NCT04184050: Phase 1/2: Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM


HPN217

A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM


Sponsor


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT04184050


Official Title: A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma


First Posted : December 3, 2019


Click here to see details on ClinicalTrials.gov

 

Drug: HPN217

BCMA/CD3e Tri-specific T-cell Activating Construct HPN217 (Code C171631)

Anti-BCMA/CD3e TriTAC HPN217

BCMA/CD3 Tri-specific T-cell Activating Construct HPN217

BCMA/CD3e Tri-specific T-cell Activating Construct HPN217

BCMA/CD3e TriTAC HPN217

BCMA/CD3e-specific TriTAC HPN217

HPN 217

HPN-217

HPN217

TriTAC HPN217

 

Program: Oral and Poster Abstracts


Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

Biological, Adult, Diseases, Therapies, immunotherapy, Study Population, Clinically relevant

Saturday, December 5, 2020, 7:00 AM-3:30 PM

 

Locations

United States, Arizona

United States, California

United States, Colorado

United States, Kansas

United States, New York

United States, Oregon

United States, Washington


Europe

France

Germany

Spain




コメント


コメント機能がオフになっています。
Posts Archive
bottom of page